

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6835951

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
THOMAS E. ICHIM	02/02/2021
TIMOTHY G. DIXON	02/02/2021
JAMES VELTMEYER	02/02/2021
RECEIVING PARTY DATA	
Name:	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
Street Address:	4093 OCEANSIDE BLVD.
Internal Address:	SUITE B
City:	OCEANSIDE
State/Country:	CALIFORNIA
Postal Code:	92056
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17387158
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5035463452
Email:	marc@bapalaw.com
Correspondent Name:	MARC BAUMGARTNER
Address Line 1:	2900 NW CLEARWATER DR.
Address Line 2:	SUITE 200
Address Line 4:	BEND, OREGON 97703
NAME OF SUBMITTER:	MARC BAUMGARTNER
SIGNATURE:	/Marc Baumgartner/
DATE SIGNED:	07/28/2021
Total Attachments: 3	
source=Exe_TSI_ASGN_'315,'335,'028#page1.tif	
source=Exe_TSI_ASGN_'315,'335,'028#page2.tif	
source=Exe_TSI_ASGN_'315,'335,'028#page3.tif	

ASSIGNMENT OF INVENTION AND PATENT APPLICATION

Whereas, (1) I, Thomas E. Ichim, an individual having a mailing address in Oceanside, California, (2) I, James Veltemeyer, an individual having a mailing address in Oceanside California, and (3) I, Timothy G. Dixon, an individual having a mailing address in Oceanside California, herein referred to collectively as “ASSIGNORS”, have invented new and useful innovations described in the following applications:

- a) U.S. Non-Provisional Application Serial No. 16/901,028, titled “Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase” filed on October 23rd, 2020;
- b) U.S. Provisional Application Serial No. 63/057,315, titled “Neuroprotection and Neuroregeneration by Pterostilbene and Compositions Thereof” filed on July 28th, 2020;
- c) U.S. Non-Provisional Application Serial No. 16/907,335, titled “Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity” filed on June 22nd, 2020;

herein referred to collectively as the “Inventions”.

And Whereas, Therapeutic Solutions International, Inc., with its principal place of business at 4093 Oceanside Blvd., Suite B, Oceanside, CA 92056, herein referred to as ASSIGNEE, desires to acquire the entire right, title, and interest in and to the said Inventions,

Now therefore, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNORS hereby acknowledge that they have sold, assigned, transferred, and set over, and by these presents do hereby sell, assign, and transfer, and set over unto ASSIGNEE and its successors and assigns, 100% of the following:

(A) ASSIGNORS right, title and interest in and to the Inventions described in:

- a), U.S. Non-Provisional Application Serial No. 16/901,028;
- b) U.S. Provisional Application Serial No. 63/057,315; and
- c) U.S. Non-Provisional Application Serial No. 16/907,335;

(B) any patent or reissues that claim priority to the Inventions described in:

- a), U.S. Non-Provisional Application Serial No. 16/901,028;
- b) U.S. Provisional Application Serial No. 63/057,315; and
- c) U.S. Non-Provisional Application Serial No. 16/907,335;

(C) any continuations, continuations-in-part, substitutes, or divisionals that claim priority to the Inventions described in:


- a), U.S. Non-Provisional Application Serial No. 16/901,028;
- b) U.S. Provisional Application Serial No. 63/057,315; and
- c) U.S. Non-Provisional Application Serial No. 16/907,335;

ASSIGNORS authorize and request the Commissioner for Patents to issue any resulting patent(s) as follows: 0% to ASSIGNORS and 100% to ASSIGNEE.

ASSIGNORS hereby further sell, assign, transfer and set over unto ASSIGNEE, 100% of ASSIGNORS' entire right, title, and interest in and to said inventions in the United States and every country foreign to the United States. ASSIGNORS agrees to execute all papers, give any required testimony, and perform other lawful acts, at ASSIGNEE'S expense, as ASSIGNEE may require to enable ASSIGNEE to perfect ASSIGNEE'S interest in any resulting patent of the United States and countries foreign thereto, and to acquire, hold, enforce, convey, and uphold the validity of said patent and reissues and extensions thereof, and ASSIGNEE'S interest therein.

In testimony whereof ASSIGNORS intending to be legally bound hereunto affix their signatures.


ASSIGNORS



(Thomas E. Ichim)

2-2-2021


(Date)



(James Veltmeyer)

2-2-2021

(Date)



(Timothy G. Dixon)

2-2-2021

(Date)